PD-1 Clinical Trials

4 actively recruiting trials

Also known as: immunotherapy

Pipeline

Phase 2: 4

Top Sponsors

Fudan University2
Suzhou Genhouse Bio Co., Ltd.1
Sichuan Baili Pharmaceutical Co., Ltd.1

Indications

Cancer4
Advanced Solid Tumor With Oncogenic Driver Mutations1
Patients With Advanced Solid Tumor1
Urothelial Carcinoma1
Pancreatic Cancer1

Other4 trials

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2

A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

Phase 2

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Phase 2

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.